Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $1.7 million to Alaxia SAS to expedite development and test the
The drug ALX-009 is a combination of two substances that are naturally found in healthy lungs and help the
Laboratory tests have shown that ALX-009 has been effective in killing bacteria in lung
Alaxia tested the drug against a wide range of bacterial species that infect people with CF, particularly drug-resistant bacteria such as Burkholderia cepacia complex (B. cepacia), Achromobacter xylosoxidans and some strains of
A Phase 1 clinical trial to test for safety is underway in France, where Alaxia is based. The trial should be complete by next spring, according to Dr. Benichou.